Updates
** Applied Therapeutics' APLT.O shares fall 72.1% to $2.39, set for a record single-day drop
** The U.S. FDA on Wednesday declined to approve APLT's drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter cited "deficiencies in the clinical application" for the drug, called govorestat, APLT says
** Brokerage William Blair says the letter was "unexpected and disappointing" but believes it does not increase the regulatory risk for govorestat's approval for SORD deficiency, another rare genetic metabolic condition
** Including session's losses, stock down 28.4% YTD
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.